1. Home
  2. BIIB
  3. BIIB News

Latest Biogen Inc. (BIIB) News on June 10, 2025

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?
BIIB

Zacks

5 days ago

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
BIIB

GlobeNewswire

7 days ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
BIIB

StockStory

11 days ago

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Biogen and City Therapeutics to develop RNAi therapy
BIIB

Pharmaceutical Technology

13 days ago

Biogen and City Therapeutics to develop RNAi therapy

Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal
BIIB

Insider Monkey

13 days ago

Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal

Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal
BIIB

Simply Wall St.

14 days ago

Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Deal

BIIB

MT Newswires

14 days ago

Biogen Collaborates With City Therapeutics on RNAi Drug Development

Biogen strikes RNAi deal with City; Aurion withdraws IPO
BIIB

BioPharma Dive

14 days ago

Biogen strikes RNAi deal with City; Aurion withdraws IPO

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
BIIB

GlobeNewswire

14 days ago

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

BIIB

MT Newswires

22 days ago

HSBC Adjusts Price Target on Biogen to $121 From $118, Maintains Hold Rating

BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance
BIIB

StockStory

a month ago

BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance

Why Biogen Inc. (BIIB) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom
BIIB

Insider Monkey

a month ago

Why Biogen Inc. (BIIB) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

3 Cash-Producing Stocks Skating on Thin Ice
BIIB

StockStory

a month ago

3 Cash-Producing Stocks Skating on Thin Ice

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
BIIB

StockStory

a month ago

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

BIIB

Thomson Reuters StreetEvents

a month ago

Q1 2025 Royalty Pharma PLC Earnings Call

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
BIIB

StockStory

a month ago

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offering
BIIB

Simply Wall St.

a month ago

Biogen (NasdaqGS:BIIB) Selects Multiple Co-Lead Underwriters for US$1 Billion Fixed-Income Offering

BIIB

MT Newswires

a month ago

Mizuho Cuts Price Target on Biogen to $169 From $207

2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
BIIB

StockStory

a month ago

2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore

BIIB

MT Newswires

a month ago

HC Wainwright Adjusts Price Target on Biogen to $187 From $241, Maintains Buy Rating

Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
BIIB

Simply Wall St.

a month ago

Biogen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

BIIB

Argus Research

a month ago

Analyst Report: Biogen Inc

BIIB

Argus Research

a month ago

Market Update: AMZN, BIIB, KLAC, NOV, OKE, TROW, ABNB

BIIB

MT Newswires

a month ago

Biogen Emerging as 'Leaner, Less Risky' Company, RBC Says

BIIB

MT Newswires

a month ago

TD Cowen Adjusts Price Target on Biogen to $175 From $200

BIIB

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Biogen to $196 From $197

BIIB

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Biogen to $146 From $152

BIIB

MT Newswires

a month ago

Canaccord Genuity Adjusts Price Target on Biogen to $220 From $265

BIIB

MT Newswires

a month ago

Oppenheimer Adjusts Price Target on Biogen to $205 From $255

BIIB

MT Newswires

a month ago

RBC Cuts Price Target on Biogen to $205 From $217, Keeps Outperform Rating

Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst MS Franchise ...
BIIB

GuruFocus.com

a month ago

Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst MS Franchise ...

BIIB

Thomson Reuters StreetEvents

a month ago

Q1 2025 Biogen Inc Earnings Call

BIIB

Pharmaceutical Technology

a month ago

Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off

Biogen (NasdaqGS:BIIB) Reports Q1 Revenue Growth Despite Decline in Net Income
BIIB

Simply Wall St.

a month ago

Biogen (NasdaqGS:BIIB) Reports Q1 Revenue Growth Despite Decline in Net Income

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
BIIB

Zacks

a month ago

BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut

Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BIIB

Zacks

a month ago

Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?
BIIB

Investor's Business Daily

a month ago

Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?

Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets
BIIB

StockStory

a month ago

Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets

BIIB

MT Newswires

a month ago

Biogen's Q1 Non-GAAP Earnings Fall, Revenue Rises; Trims 2025 Non-GAAP Earnings Guidance

Biogen Inc. (BIIB) Q1 Earnings Lag Estimates
BIIB

Zacks

a month ago

Biogen Inc. (BIIB) Q1 Earnings Lag Estimates

Biogen's results beat estimates on strength in rare disease drugs
BIIB

Reuters

a month ago

Biogen's results beat estimates on strength in rare disease drugs

Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 90% of the company
BIIB

Simply Wall St.

a month ago

Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 90% of the company

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
BIIB

Zacks

a month ago

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics
BIIB

Zacks

a month ago

Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics

BIIB

Thomson Reuters StreetEvents

a month ago

Q1 2025 SAGE Therapeutics Inc Earnings Call

Biogen Earnings: What To Look For From BIIB
BIIB

StockStory

a month ago

Biogen Earnings: What To Look For From BIIB

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
BIIB

Zacks

a month ago

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron
BIIB

Zacks

a month ago

The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron

BIIB

MT Newswires

a month ago

Piper Sandler Adjusts Price Target on Biogen to $115 From $135, Maintains Neutral Rating

BIIB

MT Newswires

a month ago

Truist Securities Adjusts Price Target on Biogen to $199 From $210, Maintains Buy Rating

BIIB

MT Newswires

a month ago

HSBC Downgrades Biogen to Hold From Buy, Adjusts Price Target to $118 From $342

BIIB

MT Newswires

2 months ago

RBC Cuts Price Target on Biogen to $217 From $225, Keeps Outperform Rating

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
BIIB

Zacks

2 months ago

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
BIIB

StockStory

2 months ago

1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore

Can Biogen Keep the Beat Streak Alive This Earnings Season?
BIIB

Zacks

2 months ago

Can Biogen Keep the Beat Streak Alive This Earnings Season?

Biogen’s Friedreich’s ataxia treatment authorised in UK
BIIB

Pharmaceutical Technology

2 months ago

Biogen’s Friedreich’s ataxia treatment authorised in UK

BIIB

MT Newswires

2 months ago

Goldman Sachs Adjusts Price Target on Biogen to $197 From $219, Maintains Buy Rating

BIIB

MT Newswires

2 months ago

RBC Lifts Price Target on Biogen to $225 From $221, Keeps Outperform Rating

BIIB

MT Newswires

2 months ago

BMO Capital Adjusts Biogen Price Target to $128 From $139

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
BIIB

Zacks

2 months ago

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi

EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s
BIIB

Pharmaceutical Technology

2 months ago

EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s

BIIB

Associated Press Finance

2 months ago

European regulators OK Alzheimer's treatment Leqembi after initial doubts

BIIB

MT Newswires

2 months ago

Wedbush Cuts Biogen Price Target to $121 From $135, Maintains Neutral Rating

BIIB

MT Newswires

2 months ago

Update: Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
BIIB

GlobeNewswire

2 months ago

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

BIIB

MT Newswires

2 months ago

Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU

BIIB

MT Newswires

2 months ago

Goldman Sachs Adjusts Biogen's Price Target to $219 From $245, Keeps Buy Rating

BIIB

MT Newswires

2 months ago

Goldman Sachs Cuts Price Target on Biogen to $219 From $245

BIIB

MT Newswires

2 months ago

Citigroup Adjusts Price Target on Biogen to $125 From $145, Keeps Neutral Rating

BIIB

Clinical Trials Arena

2 months ago

Alzheon’s Alzheimer’s pill fails in Phase III trial

BIIB

MT Newswires

2 months ago

Guggenheim Adjusts Price Target on Biogen to $165 From $190, Maintains Buy Rating

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
BIIB

Investor's Business Daily

2 months ago

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
BIIB

Zacks

2 months ago

Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?

BIIB

MT Newswires

2 months ago

Morgan Stanley Adjusts Price Target on Biogen to $152 From $157, Keeps Equalweight Rating

BIIB

Morningstar Research

2 months ago

Analyst Report: Biogen Inc.

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?
BIIB

Investor's Business Daily

2 months ago

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

BIIB

MT Newswires

2 months ago

Argus Downgrades Biogen to Hold From Buy

BIIB

Argus Research

2 months ago

Analyst Report: Biogen Inc

BIIB

Argus Research

2 months ago

Market Digest: APD, BIIB, BJ, CNP, FE

Biogen (NasdaqGS:BIIB) Gets US FDA Fast Track For Alzheimer's Despite US$8M Settlement
BIIB

Simply Wall St.

2 months ago

Biogen (NasdaqGS:BIIB) Gets US FDA Fast Track For Alzheimer's Despite US$8M Settlement

BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
BIIB

Zacks

2 months ago

BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag

BIIB

MT Newswires

2 months ago

RBC Trims Price Target on Biogen to $221 From $225, Keeps Outperform Rating

Organon acquires Actemra biosimilar’s US rights from Biogen
BIIB

Pharmaceutical Technology

2 months ago

Organon acquires Actemra biosimilar’s US rights from Biogen

BIIB

MT Newswires

2 months ago

Biogen Says Investigational Alzheimer's Drug Receives FDA Fast Track Designation

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
BIIB

GlobeNewswire

2 months ago

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

BIIB

MT Newswires

2 months ago

Organon Acquires Tofidence for Intravenous Infusion in US

Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years
BIIB

Simply Wall St.

2 months ago

Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years

Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen
BIIB

BioPharma Dive

2 months ago

Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen

BIIB

MT Newswires

3 months ago

Biogen Signs Lease for New Global HQ in Cambridge, Massachusetts

3 Value Stocks Walking a Fine Line
BIIB

StockStory

3 months ago

3 Value Stocks Walking a Fine Line

Biogen plots new global headquarters in Kendall Square
BIIB

BioPharma Dive

3 months ago

Biogen plots new global headquarters in Kendall Square

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
BIIB

GlobeNewswire

3 months ago

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?
BIIB

Zacks

3 months ago

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
BIIB

StockStory

3 months ago

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Biogen Inc. (BIIB): Among the Most Undervalued Biotech Stocks to Invest In
BIIB

Insider Monkey

3 months ago

Biogen Inc. (BIIB): Among the Most Undervalued Biotech Stocks to Invest In

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia
BIIB

Pharmaceutical Technology

3 months ago

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia

Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
BIIB

Zacks

3 months ago

Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?

Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
BIIB

Zacks

3 months ago

Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
BIIB

Zacks

3 months ago

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
BIIB

BioPharma Dive

3 months ago

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Share on Social Networks: